Is phentermine an inhibitor of monoamine oxidase? A critical appraisal [2]

Synapse

Volumn 32, Issue 2, 1999, Pages 141-145

  Rothman, Richard B ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; DOPAMINE TRANSPORTER; FENFLURAMINE; FLUOXETINE; MONOAMINE OXIDASE INHIBITOR; PHENTERMINE; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR;

DRUG APPROVAL; DRUG CONTRAINDICATION; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; MONOAMINERGIC SYSTEM; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SEROTONIN BLOOD LEVEL; VALVULAR HEART DISEASE;

ADRENERGIC UPTAKE INHIBITORS; BRAIN CHEMISTRY; HUMANS; MONOAMINE OXIDASE INHIBITORS; PHENTERMINE; SEROTONIN;

EID: 0033560971     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(199905)32:2<141::AID-SYN8>3.0.CO;2-R     Document Type: Letter

References (50)

1. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G, Begaud B. 1996. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. international primary pulmonary hypertension study group [see comments]. N Engl. J Med 335:609-616.
2. Anchors M. 1997. Fluoxetine is a safer alternative to fenfluramine in the medical treatment of obesity [letter]. Arch Intern Med 157:1270.
3. Anonymous. 1997. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluamine: U.S. Department of Health and Human Services Interim Public Health Recommendations November 1997. MMWR 46:1061-1065.
4. Backmann R, Dengler H, Gahl K, Greiser E, Jesdinsky HJ, Loogen F. 1972. Primary pulmonary hypertension. report of the commission of the german society for research on blood circulation. Verb Dtsch Ges Kreislaufforsch 38:134-141.
5. Balcioglu A, Wurtman RJ. 1998a. Effects of phentermine on striatal dopamine and serotonin release in conscious rats - in-vivo microdialysis study. Int J Obesity 22:325-328.
6. Balcioglu A, Wurtman RJ. 1998b. Effects of fenfluramine and phentermine (fen-phen) on dopamine and serotonin release in rat striatum: in vivo microdialysis study in conscious animals [In Process Citation]. Brain Res 813:67-72.
7. Brannan T, Prikhojan A, Martinez-Tica J, Yahr MD. 1998. In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism. J Neural Transm Park Dis Dement Sect 10:79-89.
8. Carboni E, Di Chiara G. 1989. Serotonin release estimated by transcortical dialysis in freely-moving rats. Neuroscience 32:637-645.
9. Celada P, Dolera M, Alvarez E, Artigas F 1992a. Effects of acute and chronic treatment with fluvoxamine on extracellular and platelet serotonin in the blood of major depressive patients. Relationship to clinical improvement. J Affect Disord 25:243-249.
10. Celada P, Perez J, Alvarez E, Artigas F. 1992b. Monoamine oxidase inhibitors phenelzine and brofaromine increase plasma serotonin and decrease 5-hydroxyindoleacetic acid in patients with major depression: relationship to clinical improvement. J Clin Psychopharmacol 12:309-315.
11. Celada P, Artigas F 1993. Monoamine oxidase inhibitors increase preferentially extracellular 5-hydroxytryptamine in the midbrain raphe nuclei. A brain microdialysis study in the awake rat. Naunyn Schmiedebergs Arch Pharmacol 347:583-590.
12. Celada P, Martin F, Artigas F. 1994. Effects of chronic treatment with dexfenfluramine on serotonin in rat blood, brain and lung tissue. Life Sci 55:1237-1243.
13. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Schaff HV, 1997. Valvular heart disease associated with fenfluramine-phentermine. N Eng J Med 337:581-588.
14. Copper JR, Bloom FE, Roth RH. The biochemical basis of neuropharmacology. New York: Oxford University Press; 1991. p 220-284.
15. Dhurandhar NV, Atkinson RI. 1996. Comparison of serotonin agonists in combination with phentermine for treatment of obesity. NAASO Conference, 3231.(Abstract)
16. Donnelly M, Rapoport JL, Potter WZ, Oliver J, Keysor CS, Murphy DL. 1989. Fenfluramine and dextroamphetamine treatment of childhood hyperactivity. Clinical and biochemical findings. Arch Gen Psychiatry 46:205-212.
17. Douglas A, Douglas JG, Robertson CE, Munro JF. 1983. Plasma phentermine levels, weight loss and side-effects. Int J Obes 7:591-595.
18. Garrick NA, Murphy DL. 1980. Species differences in the deamination of dopamine and other substrates for monoamine oxidase in brain. Psychopharmacology, 72:27-33.
19. Gerlach M, Riederer P, Youdim MB. 1992. The molecular pharmacology of L-deprenyl. Eur J Pharmacol Mol Pharmacol. Sect 226:97-108.
20. Griffen L, Anchors M. 1998. The "phen-pro" diet drug combination is not associated with valvular heart disease. Arch Intern Med 158: 1278-1279.
21. Halladay AK, Fisher H, Wagner GC. 1998. Interaction of phentermine plus fenfluramine - neurochemical and neurotoxic effects. Neurotoxicology 19:177-183.
22. Heinonen EH, Lammintausta R 1991. A review of the pharmacology of selegiline. Acta Neurol Scand Suppl 136:44-59.
23. Hilton SE, Maradit H, Moller HJ. 1997. Serotonin syndrome and drug combinations: focus on MAOI and RIMA. Eur Arch Psychiatry Clin Neurosci 247:113-119.
24. Hyttel J, Overo KF, Arnt J. 1984. Biochemical effects and drug levels in rats after long-term treatment with the specific 5-HT-uptake inhibitor, citalopram. Psychopharmacology. (Berl), 83:20-27.
25. Kankaanpaa A, Meririnne E, Lillsunde P, Seppala T. 1998. The acute effects of amphetamine derivatives on extracellular serotonin and dopamine levels in rat nucleus-accumbens. Pharmacol Biochem Behav 59:1003-1009.
26. Kato T, Dong B, Ishii K, Kinemuchi H. 1986. Brain dialysis: in vivo metabolism of dopamine and serotonin by monoamine oxidase Abut not B in the striatum of unrestrained rats. J Neurochem 46:1277-1282.
27. Knoll J. 1986. The pharmacology of (-)deprenyl. J. Neural. Transm. Suppl, 22:75-89.
28. Kolakowska T, Gadhvi H, Molyneux S. 1987. An open clinical trial of fenfluramine in chronic schizophrenia: a pilot study. Int Clin Psychopharmacol 2:83-88.
29. Kumagae Y, Matsui Y, Iwata N. 1991. Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359. Jpn J Pharmacol 55:121-128.
30. Maher TJ, Ulus IH, Wurtman RJ. 1999. Phentermine and other monoamine-oxidase inhibitors may increase plasma serotonin when given with fenfluramines. Lancet 353:38.
31. Mantle TJ, Tipton KF, Garrett NJ. 1976. Inhibition of monoamine oxidase by amphetamine and related compounds. Biochem Pharmacol 25:2073-2077.
32. Martin F, Artigas F. 1992. Simultaneous effects of p-chloroamphetamine, d-fenfluramine, and reserpine on free and stored 5-hydroxytryptamine in brain and blood. J Neurochem 59:1138-1144.
33. Matos FF, Rollema H, Basbaum AL. 1990. Characterization of monoamine release in the lateral hypothalamus of awake, freely moving rats using in vivo microdialysis. Brain Res 528:39-47.
34. Menys VC, Smith CC, Lewins P, Farmer RD, Noble MI. 1996. Platelet 5-hydroxytryptamine is decreased in a preliminary group of depressed patients receiving the 5-hydroxytryptamine re-uptake inhibiting drug fluoxetine. Clin Sci 91:87-92.
35. Padla D, Spoke J. 1997. Weight-loss comparison between a fluoxetine/ phentermine regimen and select common regimens: a retrospective study. Obesity Research 5:117.(Abstract)
36. Raleigh MJ, Brammer GL, Ritvo ER, Geller E, McGuire MT, Yuwiler A. 1986. Effects of chronic fenfluramine on blood serotonin, cerebrospinal fluid metabolites, behavior in monkeys. Psychopharmacology 90:503-508.
37. Redmon B, Raatz S, Bantle JP. 1997. Valvular heart disease associated with fenfluramine-phentermine. N Eng J Med 337:1772.
38. Robinson JB. 1985. Stereoselectivity and isoenzyme selectivity of monoamine oxidase inhibitors. Enantiomers of amphetamine N-methylamphetamine and deprenyl. Biochem Pharmacol 34:4105-4108.
39. Salazar DE, Chaikin PC, Swanson BN, Raymond RH. 1994. The effects of nefazodone and fluoxetine on platlet serotonin and whole blood serotonin. Am Soc Clin Pharmacol Ther 55:137 (PI55).(Abstract)
40. Saura J, Kettler R, Da Prada M, Richards JG. 1992. Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J Neurosci 12:1977-1999.
41. Schnabel KF, Schulz V, Busch S, Just H. 1976. Drug-induced primary vascular pulmonary hypertension. Med Welt 27:1300-1303.
42. Schoepp DD, Azzaro A . 1981. Specificity of endogenous substrates for types A and B monoamine oxidase in rat striatum. J Neurochem 36:2025-2031.
43. Scorza MC, Carrau C, Silveira R, Zapata-Torres G, Cassels BK, Reyes-Parada M. 1997. Monoamine oxidase inhibitory properties of some methoxylated and alkylthio amphetamine derivatives: structure-activity relationships. Biochem Pharmacol 54:1361-1369.
44. Shoaib M, Baumann MH, Rothman RB, Goldberg SR, Schindler CW. 1997. Behavioural and neurochemical characteristics of phentermine and fenfluramine administered separately and as a mixture in rats. Psychopharmacology. (Berl), 131:296-306.
45. Sporer KA.. 1995. The serotonin syndrome. Implicated drugs, pathophysiology and management. Drug Saf 13:94-104.
46. Sternbach H. 1991. The serotonin syndrome [see comments]. Am J Psychiatry 148:705-713.
47. Strolin Benedetti M, Dostert P. 1987. Overview of the present state of MAO inhibitors. J Neural Trans Suppl 23:103-119.
48. Stubbs EG, Budden SS, Jackson RH, Terdal LG, Ritvo ER. 1986. Effects of fenfluramine on eight outpatients with the syndrome of autism. Dev Med Child Neurol 28:229-235.
49. Youdim MB. 1988. Platelet monoamine oxidase B: use and misuse. Experientia, 44:137-141.
50. Zametkin A, Rapoport JL, Murphy DL, Linnoila M, Karoum F, Potter WZ, Ismond D. 1985. Treatment of hyperactive children with monoamine oxidase inhibitors. II. Plasma and urinary monoamine findings after treatment. Arch Gen Psychiatry 42:969-973.